Important roles have been suggested for caspase-8, caspase-9 and Apaf-1 in controlling tumor development and their sensitivity to chemotherapeutic agents. Methylation and deletion of Apaf-1 and CASP8 results in the loss of their expression in melanoma and neuroblastoma, respectively, while CASP9 localization to 1p36.1 suggests it is a good candidate tumor suppressor. The status of CASP9 and Apaf-1 expression in numerous neuroblastoma cell lines with/without ampli®ed MYCN and chromosome 1p36 loss-of-heterozygosity (LOH) was therefore examined to test the hypothesis that one or both of these genes are tumor suppressors in neuroblastoma. Although CASP9 is included in the region encompassing 1p36 LOH in all neuroblastoma cell lines examined, the remaining CASP9 allele(s) express a functional caspase-9 enzyme. Apaf-1 is also expressed in all neuroblastoma tumor cell lines examined. Thus, the CASP9 or Apaf-1 genes do not appear to function as tumor suppressors in MYCN ampli®ed neuroblastomas. However, *20% of the neuroblastoma cell lines with methylated CASP8 alleles are also highly resistant to staurosporine (STS)-and radiation-induced cell death, presumably because cytochrome c is not released from mitochondria. This suggests that a second, smaller subgroup of MYCN ampli®ed neuroblastoma tumors exists with defect(s) in apoptotic signaling components upstream of caspase-9 and Apaf-1. Since no consistent dierences in Bcl-2, Bcl-x L or Bax expression were seen in the STS-and radiation-resistant neuroblastomas, it suggests that a unique mitochondrial signaling factor(s) is responsible for the defect in cytochrome c release in this sub-group of tumors.
Introduction
Neuroblastoma is one of the most common pediatric solid tumors, and it is commonly classi®ed by the stage of tumor development (Brodeur et al., 1992) . Early stage neuroblastoma tumors (i.e., stages I, II and III) are readily treatable with chemotherapeutic drugs and irradiation, and many will even spontaneously regress. However, the prognosis for late stage tumors, especially stage IV tumors, and stage IV tumors that overexpress the oncoprotein N-Myc due to ampli®ca-tion of the corresponding MYCN gene, is not favorable (Caron, 1995) . While these late stage tumors may initially respond positively to treatment, tumors from this group are particularly aggressive since they often become increasingly resistant to chemotherapeutic drugs and irradiation-induced apoptosis following their initial exposure to these agents and relapse is common. The prognosis for treatment and potential recovery of patients with this sub-group of neuroblastoma tumors is therefore very poor. A ®fth stage of neuroblastoma tumor, stage IVS, represents a disseminated form of the disease involving multiple organs/tissues, including the liver, skin, and bone marrow, and its prognosis is much better than stage IV disease (Brodeur et al., 1992) . Knudson and Meadows (1980) suggested that stage IVS neuroblastoma represents a collection of non-malignant neural crest cells containing a mutation that interferes with their ability to undergo normal dierentiation.
In an attempt to identify potential tumor suppressor genes in the stage IV neuroblastomas that contribute to the more aggressive tumor cell phenotype, we recently analysed the expression and function of a large number of apoptotic genes in both tumor cell lines and patient tumor samples. We found that a high percentage of stage IV neuroblastoma cell lines with MYCN ampli®cation (i.e., 15/16 or 94%), as well as stage IV primary patient tumor samples with MYCN ampli®ca-tion (i.e., 10/16 or 63%), did not express caspase-8 mRNA (Teitz et al., 2000; Takita et al., 2001) . Caspase-8 is a cysteine protease that has an essential and non-redundant role in receptor-mediated cell death (Scadi et al., 1997) . This protease also appears to be an important component of some, but not all, chemotherapeutic drug-mediated apoptotic pathways in certain solid tumor cell types Engels et al., 2000; Kuwana et al., 1998) . The latter studies, as well as a separate study demonstrating that the cytolinker plectin is a major caspase-8 substrate (Stegh et al., 2000) , suggest that caspase-8 can function as both an initiator and eector caspase. Perhaps more importantly, we also found that the complete loss of caspase-8 mRNA was primarily restricted to stage IV neuroblastomas with ampli®ed MYCN in the patients studied (9/10 were stage IV, while the remaining patient tumor was stage II). All stage IV and IVS patients without ampli®ed MYCN from this study may have had a single methylated allele, but the remaining allele continued to express caspase-8 (Teitz et al., 2000) . Similar observations were made in an independent genetic study of a cohort of Japanese neuroblastoma patient tumors (Takita et al., 2001) .
The CASP8 gene was either deleted or silenced by methylation in the neuroblastoma cell lines, while CASP8 was primarily silenced through the methylation of its promoter sequences in the primary patient tumor samples (Teitz et al., 2000) . The programmed reexpression of caspase-8 in the neuroblastoma cell lines resensitized the tumor cells to death receptor-mediated, drug-induced and survival factor-dependent apoptotic signals. Additional studies veri®ed that CASP8 methylation resulted in the loss of caspase-8 expression in neuroblastoma cell lines as well as in primitive neuroectodermal brain tumors (PNETs) (Eggert et al., 2001; Grotzer et al., 2000) . In separate, and more recent, experiments it has been shown that Apaf-1 expression is lost in a group of melanoma tumor cell lines and patient samples due to methylation and deletion of the Apaf-1 gene (Soengas et al., 2001) . These data suggest that a common mechanism involving epigenetic gene silencing may be involved in the speci®c loss of certain apoptotic regulators. Of possible signi®cance is the fact that both neuroblastoma and melanoma tumors are derived from the same neural crest progenitor cells (LaBonne and BronnerFraser, 1999) . We therefore decided to analyse the status of caspase-9 and Apaf-1 expression and activity, as well as mitochondrial release of cytochrome c, using the neuroblastoma cell lines from our previous study, to determine whether these genes are also inactivated in neuroblastoma. Speci®cally, is caspase-9 and/or Apaf-1 expression or activity aected within the larger subgroup of neuroblastomas with ampli®ed MYCN and methylated CASP8 (i.e., 94% of the cell lines and 63% of the patient material)? Alternatively, are defects in their expression or activity restricted to the smaller sub-group (i.e., 6% of the cell lines and 37% of the patient samples) of tumors that do not completely silence CASP8 via methylation? The inactivation of CASP9 by deletion, mutation and/or methylation might help to explain the defects in apoptotic signaling observed in the 37% of tumors that did not silence CASP8.
Caspase-9 is an initiator caspase that plays a crucial role in many forms of drug-induced cell death triggered by release of cytochrome c from the mitochondria into the cytosol (see review in refs. Gastman et al., 2000; Kuida et al., 1998; Soengas et al., 1999) . Upon the release of cytochrome c into the cytosol, procaspase-9 is activated through the formation of a multi-protein complex, termed an`apoptosome', by the binding of cytochrome c to the activating factor Apaf-1 (Saleh et al., 1999) . Once the apoptosome is formed and caspase-9 activated, downstream eector caspases, such as caspase-3, can then be activated to promote the cell death program. It has also been reported that procaspase-9 can be activated without modi®cation due to proteolytic cleavage (Stennicke et al., 1999) . Considering several recent studies (Soengas et al., 1999) , CASP9 seemed a promising candidate tumor suppressor gene in neuroblastomas with ampli®ed MYCN. First, human CASP9 is localized to chromosome 1 band 34-36.1 (Soengas et al., 1999) . Numerous reports have shown that the loss of heterozygosity (LOH) of chromosome region 1p36 frequently occurs in MYCN ampli®ed neuroblastomas, suggesting that the loss of a tumor suppressor gene, or genes, within this chromosome region is necessary for the survival of tumor cells overexpressing N-Myc (Caron et al., 1993) . Second, Soengas et al. (1999) found that Casp9 7/7 mouse embryo ®broblast (MEF) cells are no longer sensitized to the c-myc-induced apoptotic signal, and that Casp9 7/7 MEFs co-expressing c-Myc and Ras exhibited enhanced tumorigenicity when compared to c-Myc/Ras MEFs in immunocompromised mice. And third, Gerard Evan and colleagues have shown that cMyc-induced sensitization to apoptotic signals is mediated through the inappropriate release of cytochrome c from the mitochondria into the cytosol (Juin et al., 1999) . The potential signi®cance of these ®ndings regarding a possible role for caspase-9 in controlling the development of childhood neuroblastoma tumors with 1p36 LOH and MYCN gene ampli®cation is therefore clear.
Results

CASP9 gene deletion in human neuroblastoma cell lines with, and without, 1p36 LOH
In an eort to determine whether the CASP9 locus was altered in neuroblastoma, particularly in those tumors with 1p36 LOH and ampli®ed MYCN, we isolated three human CASP9 BAC clones for use in¯uores-cence in situ hybridization (FISH) experiments (Teitz et al., 2000) . After con®rming that these BACs contained the CASP9 gene by DNA sequencing, FISH analysis was performed. The results con®rmed that CASP9 was, indeed, localized to the 35 ± 36 region of the short (p) arm of chromosome 1 (data not shown). To delineate the size of the deletion in this region of chromosome 1 a separate set of FISH experiments was performed using a TNFR2 BAC probe that is slightly more centromeric than CASP9, or a CDC2L1 BAC probe that is more telomeric than CASP9. By conducting fractional length measurements of 10 hybridized Oncogene Caspase-9, Apaf-1 and neuroblastoma T Teitz et al chromosomes is from normal lymphocytes we found that CASP9 is located at position 1p36.13 ± 1p36.21 (data not shown). Additional FISH experiments were then performed on the neuroblastoma cell lines that had been previously characterized with regard to their CASP8 status, using both a Casp9 BAC probe and a chromosome 1 centromere repeat probe. Similar to CDC2L1 and TNFR2, which are frequently deleted/ translocated in neuroblastoma cell lines with ampli®ed MYCN (Teitz et al., 2000) , one allele of CASP9 was either deleted or translocated to another chromosome in tumor cells with MYCN ampli®cation (Table 1 ). In addition, one allele of CASP9 was deleted or translocated in several neuroblastoma cell lines that did not contain ampli®ed MYCN (Table 1) .
Caspase-9 and Apaf-1 expression and activity in human neuroblastoma cell lines
To ascertain whether the remaining CASP9 allele(s) were producing an active enzyme, equal amounts of the lysates from untreated and staurosporine (STS)-treated cells were examined by immunoblotting using a caspase-9 antibody as previously described by this laboratory (Tang et al., 1999 (Tang et al., , 2000 . Activation of the procaspase-9 enzyme by autoproteolysis generates a p17 subunit (Saleh et al., 1999) . This subunit was readily detected by immunoblotting in all of the neuroblastoma cell lines ( Figure 1a and Table 1) , although the level of this subunit was greatly reduced in NB12, NB13 and NB15. These variations in the level of intensity of the caspase-9 p17 subunit in these cell lines (data not shown) suggest that they may be haploinsucient for this enzyme. Furthermore, caspase-9 RNase protection analysis revealed equivalent levels of mRNA in all NB cell lines (Table 1) . DNA sequence analysis of reverse transcriptase-polymerase chain reaction (RT ± PCR) products corresponding to caspase-9 mRNA from neuroblastoma cell lines, including NB15, with, and without, 1p36 deletions and MYCN gene ampli®cation was performed to determine whether functionally relevant point mutations were present in the CASP9 gene. This RT ± PCR analysis of caspase-9 mRNA demonstrated that its cognate sequence was normal (Table 1) . Finally, Apaf-1 expression was analysed by immunoblotting all NB cell lines with an hApaf-1-speci®c antibody (Figure 1b ). Immunoblot analysis of the untreated and STS-treated cell lysates was performed, using cytosolic proteins from cells treated with this drug in at least three dierent experiments, to determine whether cytochrome c was released appropriately from the mitochondria of these neuroblastoma cells after STS treatment. In all but three of the neuroblastoma cell lines examined (i.e., NB12, NB13 and NB15), cytochrome c was, indeed, released from the mitochondria appropriately following exposure to 1.0 mM STS ( Figure 1c ). To control for loading of mitochondrial proteins that might contaminate the cytoplasm due to mitochondrial rupture, a cytochrome oxidase antibody was used as described by our laboratory previously (data not shown) (Tang et al., 1999 (Tang et al., , 2000 .
We next determined whether downstream eector caspases were activated and if their cellular substrates were being targeted. Processing of procaspase-3 into its active heteromeric subunits was observed, as well as the processing of the 116 kDa form of poly(ADPribose) polymerase (PARP) (Figure 1d ). PARP is known to be cleaved downstream of caspase-3 activation to generate a smaller 85 kDa protein only after either procaspase-8 is activated via death receptors or procaspase-9 is processed and the active 
a from RNase protection analysis; b from the direct DNA sequencing of the CASP9 gene in these cell lines. All exons and their junctions were sequenced from this representative group of NB cell lines. It was not determined in those denoted ND; c from Teitz et al. (2000) . and references therein; d from the direct DNA sequencing of the p53 gene in these cell lines Caspase-9, Apaf-1 and neuroblastoma T Teitz et al caspase-9/Apaf-1/cytochrome c apoptosome is formed (Gu et al., 1995) . Therefore, this immunoblot assay provided a convenient method that allowed us to ascertain whether caspase-3 was activated appropriately following STS treatment and procaspase-9 processing, as well as to determine whether cellular substrates were being processed correctly. Figure 1 (d) shows that PARP was processed appropriately, with the majority of the 116 kDa form of the protein being cleaved to generate the 85 kDa form in all but three neuroblastoma cell lines; namely NB12, NB13 and NB15.
Altered sensitivity to STS-and radiation-induced apoptosis in a sub-group of human neuroblastoma cell lines
Although no abnormalities were detected in procaspase-9 or Apaf-1 expression or activity in any of the neuroblastoma cell lines, we found that the dierent Figure 1 Immunoblot analysis of caspase-9, Apaf-1, cytochrome c, and PARP from neuroblastoma cell lines with and without ampli®ed MYCN. (a) Immunoblot analysis of caspase-9 from STS-treated (+) and untreated (7) NB cell lines. The size of the mature procaspase-9 (caspase-9) and one of its active subunits (p17) is indicated to the right. (b) Apaf-1 expression as determined by immunoblotting for each of the NB cell lines. (c) Cytochrome c release from the mitochondria into the cytosol of a group of NB cell lines (required for caspase-9 activation) is shown for cells that have not been (7) or have been (+) exposed to 1.0 mM STS for 2 h. Equal protein loading was determined by actin immunoblot, and for the loading of mitochondrial proteins in panel c, and control for possible mitochondrial rupture, a cytochrome oxidase antibody was used as described by our laboratory previously (Tang et al., 1999 (Tang et al., , 2000 . (d) Cleavage of the nuclear caspase substrate PARP in the presence (+) or absence (7) of STS. The generation of the 85 kDa PARP subunit requires the activation of procaspase-9 and the subsequent activation of downstream eector caspases (e.g., caspase-3)
Oncogene Caspase-9, Apaf-1 and neuroblastoma T Teitz et al cell lines varied with regard to their sensitivity to STS and g-irradiation ( Figure 2 and Table 1 ). The majority of NB cell lines underwent 70 ± 100% cell death after treatment with 1.0 mM STS within 4 h (group 1; NB1, NB5, NB7, NB8, NB14, NB16, NB17, NB19 and NB20), while four demonstrated only moderate sensitivity (i.e., 30 ± 45% cell death after 4 h; group 2; NB2, NB4, NB6 and NB10). However, three of the neuroblastoma cell lines were extremely resistant to the drug treatment, exhibiting 510% cell death after 4 h exposure to 1.0 mM STS (group 3; NB12, NB13 and NB15). In addition, exposure to g-irradiation resulted in a similar ®nding, albeit over a longer time course following initial exposure (Table 1) . STS and girradiation are known to activate apoptosis in cells through the release of cytochrome c from the mitochondria (Bertrand et al., 1994) . If one compares the amount of cytochrome c present in the cytosol after STS treatment (Figure 1c ) with the survival data in Figure 2 , only the three highly resistant neuroblastoma Figure 2 Ecacy of STS-induced apoptosis in the NB cell lines as assessed by the presence of annexin V on the outer surface of their cellular membrane. The various NB cell lines were sub-grouped according to their relative resistance to STS. Group 1 NB cell lines underwent rapid apoptosis after exposure to STS, whereas Group 3 NB cell lines were almost completely resistant to STSinduced apoptosis after 4 h exposure Caspase-9, Apaf-1 and neuroblastoma T Teitz et al cell lines (i.e., NB12, NB13 and NB15) fail to release any cytochrome c after 4 h. This data strongly suggests that defect(s) in the mechanism(s) responsible for cytochrome c release may, at least to some extent, account for the low level of apoptosis observed in these cell lines. To con®rm this, cell microinjection experiments were performed in which exogenous cytochrome c protein and a¯uorescent marker protein were introduced into the cytoplasm of one of the resistant cell lines, NB12, and the cells then exposed to 1.0 mM STS. These experiments revealed that the NB12 cells were potently resensitized to STS (Figure 3) . The NB12 cells that were injected with cytochrome c and exposed to 1.0 mM STS underwent robust apoptosis within 2 ± 3 h, while the injection of the same concentration of a control protein ± bovine serum albumin ± did not cause cell death. All microinjection experiments were performed a minimum of three dierent times with identical results (data not shown). Similar microinjection experiments were performed using the NB13 and NB15 cell lines, once again with identical results (data not shown). Thus, the apoptotic defect in the STS-and radiation-resistant neuroblastoma cell lines appears to involve the caspase-9 pathway, but the defect is located upstream of caspase-9 and Apaf-1 and the target is most likely involved in triggering or facilitating cytochrome c release from the mitochondria.
Expression of both anti-and pro-apoptotic Bcl-2 family members in neuroblastoma cell lines
Since both the anti-and pro-apoptotic members of the Bcl-2 family have been linked to mitochondrial changes, including the release of cytochrome c, these results immediately suggested that aberrant expression of a Bcl-2 family member might be involved in conferring resistance to cell death (Reed, 1997; Gross et al., 1999a) . We therefore examined the expression of the anti-apoptotic Bcl-2 and Bcl-x L proteins as well as the pro-apoptotic family member Bax. Immunoblot analysis of lysates from the untreated and STS treated neuroblastoma cell lines from group 3 did not reveal any conclusive link between the altered expression of these Bcl-2 family members and resistance to STSinduced apoptosis (Figure 4 ). While Bcl-2 is expressed in many of the neuroblastoma cell lines, it is not expressed in all of them (Figure 4 , top panel). In addition, Bcl-2 levels are actually induced in several of the STS treated neuroblastoma cell lines (i.e., NB2, NB4 and NB8). The induction of Bcl-2 protein levels in NB2 and NB4 may contribute to their intermediate level of resistance, but its induction in NB8 does not aect STS-induced cell death in this group 1 cell line (highly sensitive). No apparent, signi®cant change in the level of the Bcl-x L protein is seen in any of the neuroblastoma cell lines either (Figure 4 , middle panel). Finally, the Bax protein is induced after STS treatment in NB17 (a highly sensitive group 1 cell line), but not in any of the other cell lines (Figure 4 , bottom panel). This might suggest that Bax is functionally relevant for STS-induced apoptosis in NB17, but it is not a generally consistent phenomenon. It should be emphasized that the speci®c mechanism(s) involved in cytochrome c release is/are not clear at this time. One possibility is that some unidenti®ed protein, or group of proteins, is required for Figure 3 Ability of exogenously introduced cytochrome c to facilitate STS-induced apoptosis in a previously STS-resistant NB cell line. Shown is one example of cytochrome c microinjected into the cytoplasm, along with a rhodamine-labeled dextran marker, of the NB12 cell line, a STS-resistant cell line. As shown, these cells begin to undergo normal apoptosis within 4 h of exposure to 1.0 mM STS. Phase microscopy of the cell ®eld, indirect immuno¯uorescence microscopy of the rhodamine-labeled dextran marker/ cytochrome c, as well as Hoescht staining of nuclei from the same cells, demonstrating the chromatin condensation that is part of the apoptotic cell phenotype, is presented. The arrows indicate the cells being compared between each of the three ®elds shown (phase, immuno¯uorescence, and Hoescht). Finally, a BSA control is included below the NB12 cells microinjected with cytochrome c, with the same three ®elds and arrows delineating the cells being compared between the various ®elds Oncogene Caspase-9, Apaf-1 and neuroblastoma T Teitz et al cytochrome c release to occur. It is also possible that a number of dierent proteins can facilitate the release of cytochrome c, perhaps in a signal and/or cell-type speci®c manner. A number of additional proteins also in¯uence the release of cytochrome c from mitochondria. The anti-and pro-apoptotic Bcl-2 family members (Reed, 1997; Gross et al., 1999a) , apoptotic inducing factor (AIF) (Daugas et al., 2000) , and SMAC/DIABLO, which regulates caspase-9 activity by its opposing eects on caspase-9 and the caspase-9 inhibitor XIAP (Verhagen et al., 2000; Du et al., 2000) , are examples. In addition, various transporter proteins, such as the voltage-dependent anion channel (VDAC), have also been implicated in the release of cytochrome c from mitochondria when associated with proapoptotic Bcl-2 family members such as Bax and Bak (Shimizu et al., 2001) . Finally, post-translational modi®cations (e.g., phosphorylation and dephosphorylation as well as N-myristoylation) of one or more of the proteins capable of forming, or inducing the formation of, functional membrane pores are possible (Zha et al., 2000; Kennedy et al., 1999; Zhou et al., 2000) . The phosphorylation of pro-apoptotic Bcl-2-related family members by the survival protein kinase AKT (Kennedy et al., 1999; Zhou et al., 2000; Asselin et al., 2001) , as well as the N-myristoylation of the caspase processed form of Bid, tBid (Zha et al., 2000) , are examples of potential modi®cations which result in diminished apoptosis. Both of these modi®cations result in profound changes in the ability of these proteins to promote the release of cytochrome c from mitochondria. Future studies should address the molecular mechanism of the inactivation of this step in the drug-induced apoptosis pathway within this subgroup of neuroblastoma tumor cell lines.
Status and expression of the p53 tumor suppressor gene in the neuroblastoma cell lines
The tumor suppressor protein p53 is known to sense stress signals and to help propagate drug-induced cell death signals, most likely through the release of cytochrome c from mitochondria (Chen et al., 1996; Lowe et al., 1993; Schuler et al., 2000) , although the exact mechanism(s) are still not absolutely resolved. It should be noted, however, for the purpose of this study that STS can induce a moderate degree of apoptosis in p53 7/7 ®broblasts (Slee et al., 2000) , clearly indicating Figure 4 Immunoblot analyses of three dierent anti-and pro-apoptotic members of the Bcl-2 protein family, Bcl-2, Bcl-x L , and Bax from the NB cell lines. NB cell lines were treated (+) or untreated (7) with 1.0 mM STS for 4 h. Cell lysates were isolated from these cell lines and then immunoblotted sequentially with anti serum to the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-x L or antiserum to the pro-apoptotic Bcl-2 family member Bax (as indicated to the right of each panel). An actin protein loading control immunoblot is shown in the panel at the bottom of this ®gure that p53 is not necessarily required for STS to elicit an apoptotic response. Even so, p53 can modulate and enhance the STS-induced apoptotic response to some extent. Evidence exists for p53-dependent activation of the caspase-9 apoptosome (Soengas et al., 1999) , as well as an essential role for capase-8 in transcriptionindependent apoptosis triggered by p53 (Ferreira et al., 2000) . Furthermore, it has recently been demonstrated that while primary, untreated neuroblastoma tumors rarely harbor p53 mutations, chemotherapeutic drug treatment can induce p53 gene mutations in neuroblastoma tumors (Tweddle et al., 2001) . In an attempt to examine the functional status of the p53 protein in the neuroblastoma cell lines being used for these studies, p53 response to irradiation (10 Gy) was looked at by immunoblotting. In 10 of the neuroblastoma cell lines tested we found that the p53 gene product was at consistent, high levels and that it was not induced by IR-treatment ( Figure 5 ). In the three STS-resistant neuroblastoma cell lines no correlation between caspase-8 inactivation and p53 status was found (Table  1 and Figure 5 ). Furthermore, there was no apparent correlation between resistance to g-irradiation-induced apoptosis and p53 status (Table 1 and Figure 5 ). As additional veri®cation of these results we decided to determine the sequence status of p53 from all of the neuroblastoma cell lines used in this study by analysis of RT ± PCR products, as well as through the use of mutant-speci®c p53 antibodies. In eight of the cell lines we detected point mutations or deletions in the DNA-binding domain of p53 that could aect the activity of the protein (Table 1) . While p53 mutations were found in three neuroblastoma cell lines that demonstrated resistance to STS-induced apoptosis (i.e., NB12, NB13 and NB15), microinjection of cytochrome c eciently induced apoptosis in all of these cell lines (for an example see Figure 3 and Table  1 ). These data indicate that cytochrome c release occurs within these cells, in all likelihood, independently of p53 function. Furthermore, in neuroblastoma cell lines that contained mutant forms of p53 (e.g., NB4, NB5, NB6, NB8, NB10, NB14 and NB20) cytochrome c release still occurred appropriately (Figure 1c ). In addition, even though cell death was impaired to some extent in a sub-group of these tumor cell lines (i.e., NB4, NB8 and NB10) it was also impaired in NB2, which contains wild-type p53 (Figures 1c and 2 ). This is an important point, and may re¯ect the ability of neuroblastoma tumor cells to acquire speci®c mutations that promote their survival. It appears that p53 is not required for apoptosis induced by STS in this setting (see Figure 2) , particularly since ®ve additional neuroblastoma cell lines showed moderate to no resistance to STSinduced cell death (Figures 2 and 5 and Table 1 ). Therefore, while it is possible that p53 inactivation may play a role in the observed defect in cytochrome c release in NB12, NB13 and NB15, such inactivation is de®nitely not sucient by itself to explain the almost complete abrogation of cytochrome c release in these cell lines.
Discussion
In summary, our studies appear to have ruled out the possibility that either the Caspase-9 or Apaf-1 genes are common tumor suppressor genes in MYCN ampli®ed neuroblastomas. Similarly, Bala et al. (2000) have shown that Apaf-1 is not mutated in male germ cell tumors. Interestingly, Apaf-1 is inactivated in a subgroup of melanoma tumors, and the data suggests that this inactivation also occurs via methylation of the corresponding gene in the tumor cell (Soengas et al., 2001) . Importantly, caspase-9 was expressed and active in these melanomas as well. Here we have shown that while neither caspase-9 or Apaf-1 is silenced or their function signi®cantly altered in 14 MYCN ampli®ed and two non-MYCN ampli®ed neuroblastomas, a separate event(s) aecting an upstream regulator, or regulators, of this pathway is aected in a small subgroup of these tumor cell lines. Caspase-8 is also silenced in this sub-group of tumor cell lines, and it has been demonstrated that programmed expression of caspase-8 is, on its own, sucient to re-sensitize these cells to certain apoptotic insults (Teitz et al., 2000) . Since this current study involves only a large cohort of neuroblastoma tumor cell lines, we cannot conclude whether similar events involving an upstream regulator(s) of the caspase-9 pathway occur in vivo. Based upon the source of the tumor cell lines and patient material that is aected, one might predict that the inactivation of Apaf-1 and/or CASP8 in human tumors is most likely a very tumor-type speci®c event. Twenty Figure 5 The various NB cell lines were immunoblotted with a p53 antibody before and after g-irradiation to determine the status of the p53 protein. The same NB cell lines used in the previous studies were also examined with a p53 antibody that detects wildtype and mutant p53 protein of human origin prior to, and after, exposure of these cells to 10 Gy of g-irradiation Oncogene Caspase-9, Apaf-1 and neuroblastoma T Teitz et al per cent of the neuroblastoma cell lines tested here demonstrated an extremely high resistance to STS. Although these cell lines also contain mutations in p53, they most likely acquired an additional genetic defect that completely abolishes their ability to release cytochrome c into the cytosol as a result of STS treatment, particularly since STS is capable of inducing apoptosis in p53 7/7 ®broblasts (Slee et al., 2000) . Finally, analysis of these same neuroblastoma cell lines with various multi-drug resistance (e.g., MDR1) cDNA probes did not reveal any signi®cant alteration in their level of expression (J Sampath, V Kidd and J Schuetz, unpublished results).
Of particular interest is the neural crest progenitor cell origin of both the neuroblastoma and melanoma tumors, raising the intriguing possibility that silencing of critical apoptotic regulators may be developmentally linked. In MYCN ampli®ed neuroblastomas the more common apoptotic gene target for inactivation appears to be CASP8 (Teitz et al., 2000) , and perhaps secondarily, an upstream regulator(s) that aects the activity of the caspase-9/Apaf-1/cytochrome c apoptosome through its ability to prevent the release of cytochrome c into the cytosol. Why choose dierent genes, and seemingly dierent apoptotic pathways, as targets to inactivate in tumors of similar progenitor cell origin? That may be one of the more important questions to have arisen from this and the previous studies. These studies also highlight the complexity of apoptotic signaling in response to chemotherapeutic drugs and g-irradiation.
It is also signi®cant to note that the so-called extrinsic, caspase-8 regulated, and intrinsic, caspase-9 regulated, cell death pathways appear to act synergistically to promote cell death (Engels et al., 2000; Ferreira et al., 2000; Lacour et al., 2001) , as well as promote apoptosis in a more pathwaydependent manner. For example, caspase-9/Apaf-1/ cytochrome c activation following caspase-8 activation through mediator-molecules such as BID (Gross et al., 1999b) or BAR (Zhang et al., 2000) , or alternatively, the activation of caspase-8 following caspase-9 and caspase-3 activation to augment and speed cell death (Tang et al., 2000) . Collaboration between the cellular death signals propagated by caspases-8 and -9 may explain why the inactivation of both caspases-8 and -9, or regulators of their activity such as Apaf-1, could represent a redundant process. Most likely, silencing either of these apoptotic-signaling pathways is sucient to hamper the apoptotic process and promote survival, but how these choices are made may well be cell-type speci®c.
Materials and methods
Cell lines and drugs
The NB cell lines used here have been described in detail previously (Teitz et al., 2000) . The cells were grown in RPMI 1640 (GIBCO BRL), supplemented with 10% FCS (Atlanta Biologicals, GA, USA), 2% glutamine (GIBCO BRL) and 0.1% gentamicin (GIBCO BRL) in a 378C, 5%CO 2 , humidi®ed incubator. Staurosporine was purchased from Roche, (Mannheim, Germany, cat. no. 1055682) .
FISH analysis
FISH analysis of interphase and metaphase cells was performed as previously described by this laboratory with the following probes isolated from a human BAC genomic library (Genome Systems, Inc., St. Louis, MO, USA): Casp-9 BAC; and previously isolated TNFR2 ± BAC and CDC2L1 ± BAC (Teitz et al., 2000) and a human chromosome 1 centromere repeat probe (Vysis).
DNA sequence analysis
For sequencing caspase-9 mRNA, RT ± PCR was performed using a set of six overlapping primer pairs that cover the entire caspase-9 mRNA. The sequence was compared to GenBank accession number U56390, and no amino acid changes noted. The primers used for the RT ± PCR reactions included: primer 9-1 (sense), 5'-CGGAAGCGGACTG-AGGCGGC-3', primer 9-2 (antisense), 5'-CCAATGTC-CACTGGTCTGG-3', primer 9-3 (sense), 5'-GCGAACTAA-CAGGCAAGCAG-3', primer 9-4 (antisense), 5'-ACCA-CGCAGCAGTCCAGAGC-3', primer 9-5 (sense), 5'-CG-CCGCATTTCATGGTGGAG-3' primer 9-6 (antisense), 5'-GTAGGACA-CAAAGATGTCAC-3', primer 9-7 (sense), 5'-TCCAGGAAGGTTTGAGGACC-3', primer 9-8 (antisense), 5'-TCTGGAAGCTGCTA-AGAGCC-3', primer 9-9 (sense), 5'-GGCTGA-GGCCTGGACTTTCC-3', primer 9-10 (antisense), 5'-TGATCTATGAGCGA-TACTGG-3', primer 9-11 (sense), 5'-TCTCTAGAGCAGGGA-TTAAC-3' and primer 9-12 (antisense), 5'-CCATATTTGCCTCAGATTTAT-3'.
For DNA sequence analysis of the p53 mRNA we employed the primer pair (sense) 5'-GATTGGCAGCCA-GACTGC'-3', and (antisense) 5'-GGAACAAGAAGTGGA-GAATG'-3'. The sequence was compared to GenBank accession no K03199.
Protein expression analysis
For immunoblotting and indirect immuno¯uorescence analysis, the following antibodies were used: anti-cytochrome c (Pharmingen, USA), PARP (Upstate Biotech, Lake Placid, NY, USA), anti-caspase 9 (kindly provided by Dr Xiaodang Wang, UTSW), anti-Apaf-1 (Santa Cruz Biotechnology, CA, USA), anti p53 (D0-1, Santa Cruz Biotechnology, CA, USA), anti-Bcl-2 (Santa Cruz Biotechnology, CA, USA), anti-Bcl-X L (Transduction LAB, USA), and anti-Bax (Santa Cruz Biotechnology, CA, USA).
Microinjection with cytochrome c
An Eppendorf Transjector system with a Zeiss Axiovert 135TV microscope was used to microinject and view the cells after injection. The cytoplasm of 100 ± 150 cells were microinjected with 1.0 mM cytochrome c protein (Sigma), in conjunction with a rhodamine-labeled dextran probe to mark the injected cells (Molecular Probes, USA). The microinjected cells were followed by indirect immuno¯uorescence microscopy for up to 6 h following microinjection and treatment with STS. As a control, BSA fraction V (Sigma) was microinjected into the cytoplasm of the same cells at an identical concentration along with the rhodamine-labeled dextran probe.
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Irradiation
Exponentially growing cells were treated with 10-Gy of girradiation from a 137 Cesium gamma irradiator at 1.2 Gy/min and harvested 4 h after irradiation for extraction of cellular proteins and immunoblotting, or at 4, 8 and 24 h to determine the extent of cell death. Procedures followed were identical to those used in earlier studies (Tang et al., 2000) .
Apoptosis
Apoptosis was measured after cells were treated with 1.0 mM staurosporine by annexin V staining, Tunel assay, and Hoechst 33342 staining to detect chromatin condensation. Procedures were followed as previously described in earlier publications from this laboratory (Tang et al., 2000) .
